<DOC>
	<DOCNO>NCT00527124</DOCNO>
	<brief_summary>This randomized phase II trial study well give docetaxel prednisone together without cediranib work treat patient metastatic prostate cancer respond hormone therapy . Drugs use chemotherapy , docetaxel prednisone , work different way stop growth tumor cell , either kill cell stop dividing . Cediranib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving docetaxel together prednisone , without cediranib , may kill tumor cell .</brief_summary>
	<brief_title>Docetaxel Prednisone With Without Cediranib Treating Patients With Metastatic Prostate Cancer That Did Not Respond Hormone Therapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . To determine 6-month progression-free survival rate patient hormone refractory metastatic adenocarcinoma prostate treat docetaxel prednisone v without cediranib . SECONDARY OBJECTIVES : I . To evaluate safety profile cediranib , docetaxel , prednisone patient metastatic hormone-refractory prostate cancer . II . To determine duration prostate-specific antigen ( PSA ) response PSA control patient metastatic hormone-refractory prostate cancer treat cediranib , docetaxel , prednisone . III . To determine partial complete response rate patient measurable disease treat cediranib , docetaxel , prednisone . IV . To determine time progression patient metastatic hormone-refractory prostate cancer treat cediranib , docetaxel , prednisone . V. To determine overall survival patient metastatic hormone-refractory prostate cancer . VI . To perform correlative marker study measure serum level VEGF , PDGF , sICAM , bFGF , interleukin ( IL ) -6 , IL-8 . VII . To perform pilot study [ F18 ] FMAU positron emission test ( PET ) image patient receive cediranib , docetaxel , prednisone . OUTLINE : This multicenter study . Patients stratify participate institution . Patients randomize 1 2 treatment arm . ARM I : Patients receive oral cediranib daily day 1-21 , docetaxel IV 1 hour day 1 , oral prednisone twice daily day 1-21 . ARM II : Patients receive docetaxel prednisone arm I . In arm , course repeat every 21 day absence disease progression unacceptable toxicity . Archival paraffin-embedded tissue block slide time diagnosis ( subsequent , prior therapy ) evaluate expression molecular target relevant study . Blood specimens baseline , course 1 2 , completion study treatment analyze protein marker . Samples analyze ELISA IHC angiogenesis-associated plasma protein , plasma level VEGF , tumor expression PDGFR , interleukin ( IL ) -6 IL-8 plasma level . Patients also undergo positron emission test ( PET ) scan utilizing fluorodeoxyglucose ( FDG ) baseline course 1 . After completion study treatment , patient follow every 3 month 52 week .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Clinical/radiologic metastasis objective evidence disease progression image rise prostatespecific antigen ( PSA ) despite androgen deprivation therapy Rising PSA must determine base rise trend 2 successive elevation minimum interval 1 week Meets 1 follow criterion : Measurable disease , level PSA , least 1 unidimensionally measurable lesion ( long diameter record ) &gt; = 20 mm conventional technique &gt; = 10 mm spiral CT scan , nonmeasurable disease , PSA &gt; = 5 ng/mL OR new area bony metastasis bone scan Castrate level testosterone &lt; 50 ng/dL must maintain document Luteinizing hormonereleasing hormone ( LHRH ) agonist therapy must continue , require maintain castrate level testosterone Total bilirubin normal Patients radiological evidence stable brain metastasis eligible provide asymptomatic require corticosteroid treat corticosteroid show clinical radiological evidence stabilization least 10 day discontinuation steroid ECOG performance status ( PS ) = &lt; 2 Karnofsky PS 60100 % Life expectancy &gt; 12 week Leukocytes &gt; = 3,000/mcL Absolute neutrophil count &gt; = 1,500/mcL Platelet count &gt; = 100,000/mcL Histologically confirm adenocarcinoma prostate AST ALT = &lt; 2.5 time upper limit normal Creatinine normal OR creatinine clearance &gt; = 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Proteinuria = &lt; 1+ urine protein : creatinine ratio = &lt; 1.0 OR 24hour urine protein &lt; 1,000 mg Peripheral neuropathy &gt; = grade 2 Uncontrolled intercurrent illness include , limited , follow : ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Congestive heart failure , second third degree heart block , recent myocardial infarction within past 6 month QTc prolongation &gt; 500 msec OR ECG abnormality note within 14 day treatment New York Heart Association class III IV cardiac disease ; Class II disease control treatment monitoring allow History poorly control hypertension ( e.g. , rest blood pressure &gt; 150/90 mm Hg without hypertensive therapy ) History curatively treat malignancy survival prognosis le 5 year concurrent malignancy except adequately treat basal cell squamous cell skin cancer carcinoma situ History significant gastrointestinal impairment , judge investigator , would significantly affect absorption cediranib History severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 Significant hemorrhage ( 30 mL bleeding/episode previous 3 month ) hemoptysis ( 5 mL fresh blood previous 4 week ) Prior enrollment randomization treatment present study Patients must flutamide antiandrogen therapy â‰¥ 4 week ( 6 week bicalutamide nilutamide ) No prior chemotherapy metastatic prostate cancer No major surgery within past 14 day surgical incision fully heal No HIVpositive patient combination antiretroviral therapy No condition require concurrent use drug biologics proarrhythmic potential No investigational agent within 30 day prior study enrollment No untreated unstable brain meningeal metastasis Known hypersensitivity cediranib excipients</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>